Shares of insulin and glucose monitoring stocks are trading lower. Weakness may be due to strength in diabetes and weight loss drug makers following strong data from Novo Nordisk and Mounjaro sales growth from Lilly
Portfolio Pulse from Benzinga Newsdesk
Shares of insulin and glucose monitoring companies are trading lower, possibly due to strong data from diabetes and weight loss drug makers Novo Nordisk and Lilly. This has led to increased sales growth for these companies, potentially impacting the market share of insulin and glucose monitoring companies.
August 08, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Abbott Laboratories' stock may be negatively impacted due to strong performance from Novo Nordisk and Lilly.
Abbott Laboratories, a major player in the insulin and glucose monitoring market, may see a decrease in their market share due to increased competition from Novo Nordisk and Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Dexcom's stock may be negatively impacted due to strong performance from Novo Nordisk and Lilly.
Dexcom, a major player in the insulin and glucose monitoring market, may see a decrease in their market share due to increased competition from Novo Nordisk and Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Insulet Corporation's stock may be negatively impacted due to strong performance from Novo Nordisk and Lilly.
Insulet Corporation, a major player in the insulin and glucose monitoring market, may see a decrease in their market share due to increased competition from Novo Nordisk and Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
Tandem Diabetes Care's stock may be negatively impacted due to strong performance from Novo Nordisk and Lilly.
Tandem Diabetes Care, a major player in the insulin and glucose monitoring market, may see a decrease in their market share due to increased competition from Novo Nordisk and Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75